Sensitivity to aldosterone: Plasma levels are not the full story

Hypertension

Volumn 63, Issue 6, 2014, Pages 1168-1170

  Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CREATININE; FLUDROCORTISONE; MINERALOCORTICOID RECEPTOR; OUABAIN; POTASSIUM ION; RENIN; SODIUM ION;

ALDOSTERONE BLOOD LEVEL; BLACK PERSON; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CAUCASIAN; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; NOTE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RACE DIFFERENCE; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION;

AFRICAN AMERICANS; ALDOSTERONE; BLOOD PRESSURE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE;

EID: 84902247265     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03127     Document Type: Note

References (10)

1. Tu W, Eckert GJ, Hannon TS, Liu H, Pratt LM, Wagner MA, DiMeglio LA, Jung J, Pratt JH. Racial differences in sensitivity of blood pressure to aldosterone. Hypertension. 2014;63:1212-1218.
2. Wilson TW, Gram CE. Biohistory of slavery and blood pressure differences in blacks today. A hypothesis. Hypertension. 1991;17(1 suppl):1-122-1-128.
3. Diamond J. The saltshakers curse. Natural History. 1991;100:20-26.
4. Blair-West JR, Coghlan JP, Denton DA, Goding JR, Wright RD. The effect of aldosterone, cortisol and corticosterone upon the sodium and potassium content of sheep's parotid saliva. J Clin Investig. 1963;42:484-496.
5. Shibata S, Rinehart J, Zhang J, Moeckel G, Castañeda-Bueno M, Stiegler AL, Boggon TJ, Gamba G, Lifton RP. Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab. 2013;18:660-671.
6. Funder JW. Angiotensin retains sodium by dephosphorylating mineralocorticoid receptors in renal intercalated cells. Cell Metab. 2013;18:609-610.
7. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab. 2004;89:2736-2740.
8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
9. Ori Y, Chagnac A, Korzets A, et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transpl. 2013;28:1787-1793.
10. Gouli A, Kaltsas G, Tzonou A, et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest. 2011;41:1127-1136.